Polycystic Ovary Syndrome in the Adolescent

Obstetrics and Gynecology Clinics of North America

Volumn 36, Issue 1, 2009, Pages 129-152

  Pfeifer, Samantha M ^a   Kives, Sari ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acne; Adolescent; Hirsutism; Insulin resistance; Obesity; Polycystic ovarian syndrome

Indexed keywords

ANDROSTENEDIONE; CHOLESTEROL; CONTRACEPTIVE AGENT; ESTRADIOL; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GESTAGEN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; METFORMIN; NAFARELIN; NORETHISTERONE ACETATE; PLACEBO; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN; SPIRONOLACTONE; TESTOSTERONE; THIAZOLIDINE DERIVATIVE; THYROTROPIN;

ACNE; ADOLESCENT; AMENORRHEA; ANOVULATION; ARTERIAL WALL THICKNESS; BARIATRIC SURGERY; BLOOD ANALYSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DIABETES MELLITUS; ENDOMETRIUM HYPERPLASIA; ESTHETIC SURGERY; ESTRADIOL BLOOD LEVEL; FEMALE INFERTILITY; FOLLITROPIN BLOOD LEVEL; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; HYPERKALEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER FAILURE; MENSTRUATION; MENSTRUATION DISORDER; METABOLIC SYNDROME X; OBESITY; ORAL GLUCOSE TOLERANCE TEST; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROVOCATION TEST; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; ULTRASOUND; URINARY FREQUENCY; WEIGHT REDUCTION;

ADOLESCENT; BARIATRIC SURGERY; DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; PREVALENCE; PROGNOSIS; RISK FACTORS; WEIGHT LOSS;

EID: 63449099227     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2008.12.004     Document Type: Review

References (141)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
2. Azziz R., Woods K.S., Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
3. Knochenhauer E.S., Key T.J., Kahsar-Miller M., et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
4. Kahsar-Miller M.D., Nixon C., Boots L.R., et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 75 (2001) 53-58
5. Waldstreicher J., Santoro N.F., Hall J.E., et al. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 66 (1988) 165-172
6. Apter D., Butzow T., Laughlin G.A., et al. Accelerated 24 h luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian disease. J Clin Endocrinol Metab 79 (1994) 99-125
7. Apter D., Butzow T., Laughlin G.A., et al. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Pediatr Endocrinol Metab 80 10 (1995) 2966-2973
8. Veldhuis J.D., Pincus M., Garcia-Rudaz M.C., et al. Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 86 (2001) 72-79
9. Yasin M., Dalkin A.C., Haisenleder D.J., et al. Testosterone is required for gonadotropin-releasing hormone stimulation of luteinizing hormone-P messenger ribonucleic acid expression in female rats. Endocrinology 137 (1996) 1265-1271
10. Azziz R. The time has come to simplify the evaluation of the hirsute patient. Fertil Steril 74 (2000) 870-872
11. Barbieri R.L., Makris A., Randall R.W., et al. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 62 (1986) 904-910
12. Nestler J.E., Barlascini C.O., Matt D.W., et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 68 (1989) 1027-1032
13. DeClue T.J., Shah S.C., Marchese M., et al. Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female. J Clin Endocrinol Metab 72 (1991) 1308-1311
14. Dunaif A., Segal K.R., Futterweit W., et al. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 38 9 (1989) 1165-1174
15. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 80 (2003) 252-254
16. Dunaif A. Hyperandrogenemia is necessary but not sufficient for polycystic ovary syndrome. Fertil Steril 80 (2003) 262-263
17. Dunaif A., and Thomas A. Current concepts in the polycystic ovary syndrome. Ann Rev Med 52 (2001) 401-419
18. Zhang L., Rodriguez H., Ohno S., et al. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 92 (1995) 10619-10623
19. Legro R.S., Kunselman A.R., Dodson W.C., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
20. Ehrmann D.A., Barnes R.B., Rosenfeld R.L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
21. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med 346 (2002) 393-403
22. Palmert M.R., Gordon C.M., Kartashov A.I., et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 1017-1023
23. Helmrath M.A., Brandt M.L., and Inge T.H. Adolescent obesity and bariatric surgery. Surg Clin North Am 86 (2006) 441-454
24. Cussons A.J., Watts G.F., Burke V., et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 23 (2008) 2532-2558
25. Coviello A.D., Legro R.S., and Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91 (2006) 492-497
26. Rossi B., Sukalich S., Droz J., et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab (2008 Sep 23) [Epub ahead of print]
27. Pierpoint T., McKeigue P.M., Isaacs A.J., et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51 (1998) 581-586
28. Wild S., Pierpoint T., McKeigue P., et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52 (2000) 595-600
29. Legro R.S. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev 24 (2003) 302-312
30. Montgomery B.E., Daum G.S., and Dunton C.J. Endometrial hyperplasia: a review. Obstet Gynecol Surv 59 (2004) 368-378
31. Cheung A.P. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 98 (2001) 325-331
32. Jungheim E.S., Lanzendorf S.E., Odem R.R., et al. Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome. Fertil Steril (2008 Aug 8) [Epub ahead of print]
33. Weiss J.L., Malone F.D., Emig D., et al. Obesity, obstetric complications and cesarean delivery rate-a population-based screening study. Am J Obstet Gynecol 190 (2004) 1091-1097
34. Cedergren M.I. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol 103 (2004) 219-224
35. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 23 (2008) 462-477
36. Hammond M.G., Halme J.K., and Talbert L.M. Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation. Obstet Gynecol 62 (1983) 196-202
37. Imani B., Eijkemans M.J., te Velde E.R., et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 84 (1999) 1617-1622
38. Imani B., Eijkemans M.J., te Velde E.R., et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 77 (2002) 91-97
39. Legro R.S., Barnhart H.X., Schlaff W.D., et al., for the Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356 (2007) 551-566
40. Palomba S., Orio F., Falbo A., et al. Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 3498-3503
41. Barnard L., Ferriday D., Guenther M., et al. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod 22 (2007) 2279-2286
42. Ching H.L., Burke V., and Stuckey B.G. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf) 66 (2007) 373-379
43. Trent M., Austin S.B., Rich M., et al. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 5 (2005) 107-111
44. Hollinrake E., Abreu A., Maifeld M., et al. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 87 (2007) 1369-1376
45. Ibanez L., Potau N., Zampolli M., et al. Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab 79 (1994) 1778-1784
46. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 32 (2008) 1035-1041
47. Nader S. Adrenarche and polycystic ovary syndrome: a tale of two hypotheses. J Pediatr Adolesc Gynecol 20 (2007) 353-360
48. Fernandes A.R., de Sa Rosa e Silva A.C., Romao G.S., et al. Insulin resistance in adolescents with menstrual irregularities. J Pediatr Adolesc Gynecol 18 (2005) 269-274
49. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
50. Dewailly D., Catteau-Jonard S., Reyss A.C., et al. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 91 (2006) 3922-3927
51. Welt C.K., Gudmundsson J.A., Arason G., et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 91 (2006) 4842-4848
52. Barber T.M., Wass J.A., McCarthy M.I., et al. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 66 (2007) 513-517
53. Shroff R., Syrop C.H., Davis W., et al. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 88 (2007) 1389-1395
54. Sultan C., and Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril 86 Suppl 1 (2006) S6
55. Pasquali R., and Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci 1092 (2006) 158-174
56. Chang J.R., and Coffler M.S. Polycystic ovary syndrome: early detection in the adolescent. Clin Obstet Gynecol 50 (2007) 178-187
57. Rosenfield R.L. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 787-796
58. Avvad C.K., Holeuwerger R., Silva V.C., et al. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol 15 (2001) 170-177
59. Apter D. Serum steroids and pituitary hormones in female puberty: a partly longitudinal study. Clin Endocrinol (Oxf) 12 (1980) 107-120
60. Obhrai M., Lynch S.S., Holder G., et al. Hormonal studies on women with polycystic ovaries diagnosed by ultrasound. Clin Endocrinol (Oxf) 32 (1990) 467-474
61. Dramusic V., Rajan U., Chan P., et al. Adolescent polycystic ovary syndrome. Ann N Y Acad Sci 816 (1997) 194-208
62. Dramusic V., Goh V.H., Rajan U., et al. Clinical, endocrinologic, and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. J Pediatr Adolesc Gynecol 10 (1997) 125-132
63. Rachmiel M., Kives S., Atenafu E., et al. Primary amenorrhea as a manifestation of polycystic ovarian syndrome in adolescents: a unique subgroup?. Arch Pediatr Adolesc Med 162 (2008) 521-525
64. Ibanez L., Potau N., Francois I., et al. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 83 (1998) 3558-3562
65. Hannon T.S., Janosky J., and Arslanian S.A. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 60 (2006) 759-763
66. Caprio S., Plewe G., Diamond M.P., et al. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 114 (1989) 963-967
67. Sir-Petermann T., Maliqueo M., Codner E., et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 4637-4642
68. Biro F.M., and Emans S.J. Whither PCOS? The challenges of establishing hyperandrogenism in adolescent girls. J Adolesc Health 43 (2008) 103-105
69. Lucky A.W., Biro F.M., Daniels S.R., et al. The prevalence of upper lip hair in black and white girls during puberty: a new standard. J Pediatr 138 (2001) 134-136
70. Slayden S.M., Moran C., Sams W.M., et al. Hyperandrogenemia in patients presenting with acne. Fertil Steril 75 (2001) 889-892
71. Blank S.K., Helm K.D., McCartney C.R., et al. Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci 1135 (2008) 76-84
72. Ankarberg C., and Norjavaara E. Diurnal rhythm of testosterone secretion before and throughout puberty in healthy girls: correlation with 17beta-estradiol and dehydroepiandrosterone sulfate. J Clin Endocrinol Metab 84 (1999) 975-984
73. Ehrmann D.A., Rosenfield R.L., Barnes R.B., et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327 (1992) 157-162
74. Barnes R., and Rosenfield R.L. The polycystic ovary syndrome: pathogenesis and treatment. Ann Intern Med 110 (1989) 386-399
75. Stewart P.M., Shackleton C.H., Beastall G.H., et al. 5 Alpha-reductase activity in polycystic ovary syndrome. Lancet 335 (1990) 431-433
76. Venturoli S., Porcu E., Fabbri R., et al. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab 74 (1992) 836-841
77. Azziz R., Carmina E., Dewailly D., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91 (2006) 4237-4245
78. Moll Jr. G.W., and Rosenfield R.L. Plasma free testosterone in the diagnosis of adolescent polycystic ovary syndrome. J Pediatr 102 (1983) 461-464
79. Zimmermann S., Phillips R.A., Dunaif A., et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 75 (1992) 508-513
80. Mortensen M., Rosenfield R.L., and Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab 91 (2006) 3786-3790
81. Legro R.S., Chiu P., Kunselman A.R., et al. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 90 (2005) 2571-2579
82. Lachelin G.C., Barnett M., Hopper B.R., et al. Adrenal function in normal women and women with the polycystic ovary syndrome. J Clin Endocrinol Metab 49 (1979) 892-898
83. Yoo R.Y., Sirlin C.B., Gottschalk M., et al. Ovarian imaging by magnetic resonance in obese adolescent girls with polycystic ovary syndrome: a pilot study. Fertil Steril 84 (2005) 985-995
84. Sun L., and Fu Q. Three-dimensional transrectal ultrasonography in adolescent patients with polycystic ovarian syndrome. Int J Gynaecol Obstet 98 (2007) 34-38
85. Azziz R., Hincapie L.A., Knochenhauer E.S., et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 72 (1999) 915-925
86. Azziz R., Wells G., Zacur H.A., et al. Abnormalities of 21-hydroxylase gene ratio and adrenal steroidogenesis in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to acute adrenal stimulation. J Clin Endocrinol Metab 73 (1991) 1327-1331
87. Ibanez L., Potau N., Zampolli M., et al. Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab 81 (1996) 1237-1243
88. Legro R.S., Finegood D., and Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 2694-2698
89. Legro R.S. Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 15 Suppl 5 (2002) 1367-1378
90. Fruzzetti F., Perini D., Lazzarini V., et al. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril (2008) Aug 13. [Epub ahead of print]
91. Kiddy D.S., Hamilton-Fairley D., Bush A., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 36 (1992) 105-111
92. Clark A.M., Ledger W., Galletly C., et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10 (1995) 2705-2712
93. Holte J., Bergh T., Berne C., et al. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80 (1995) 2586-2593
94. Clark A.M., Thornley B., Tomlinson L., et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 13 (1998) 1502-1505
95. Huber-Buchholz M.M., Carey D.G.P., and Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84 (1999) 1470-1474
96. Crosignani P.G., Colombo M., Vegetti W., et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropomorphic indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18 (2003) 1928-1932
97. Moran L.J., Noakes M., Clifton P.M., et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 812-819
98. Pate R.R., Pratt M., Blair S.N., et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 273 (1995) 402-407
99. Wadden T.A., et al. Behavioral treatment of obesity. Med Clin North Am 84 (2000) 441-461
100. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 6 Suppl 2 (1998) 51S-209S
101. Foster G.D., Wyatt H.R., Hill J.O., et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348 (2003) 2082-2090
102. Dansinger M.L., Gleason J.A., Griffith J.L., et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction. JAMA 293 (2005) 43-53
103. Bray G.A. Uses and misuses of the new pharmacotherapy of obesity. Ann Med 31 1 (1999) 1-3
104. Trus T.L., Pope G.D., and Finlayson S.R.G. National trends in utilization and outcomes of bariatric surgery. Surg Endosc 19 (2005) 616-620
105. National Institutes of Health Consensus Development Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med 115 (1991) 956-961
106. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
107. Maggard M.A., Shugarman L.R., Suttorp M., et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 142 (2005) 547-559
108. Deitel M., Stone E., Kassam H.A., et al. Gynecologic-obstetric changes after loss of massive excess weight following bariatric surgery. J Am Coll Nutr 7 (1988) 147-153
109. Sugerman H.J., Sugerman E.L., DeMaria E.J., et al. Bariatric surgery for severely obese adolescents. J Gastrointest Surg 7 (2003) 102-108
110. Nadler E.P., Youn H.A., Ren C.J., et al. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg 43 (2008) 141-146
111. Sheiner E., et al. Pregnancy after bariatric surgery is not associated with adverse perinatal outcome. Am J Obstet Gynecol 190 (2004) 1335-1340
112. Printen K.J., Scott D., et al. Pregnancy following gastric bypass for the treatment of morbid obesity. Am Surg 48 (1982) 363-365
113. Marceau P., Kaufman D., Biron S., et al. Outcome of pregnancies after biliopancreatic diversion. Obes Surg 14 (2004) 318-324
114. Korytkowski M.T., Mokan M., Horwitz M.J., et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80 (1995) 3327-3334
115. Jung-Hoffmann C., and Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol 156 (1987) 199-203
116. Mastorakos G., Koliopoulos C., Deligeoroglou E., et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 85 (2006) 420-427
117. Burkman R.T. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 98 1A (1995) 130S-136S
118. Thorneycroft I.H., Stanczyk F.Z., Bradshaw K.D., et al. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 60 (1999) 255-262
119. Moghetti P., Tosi F., Tosti A., et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized double blind, placebo-controlled trial. J Clin Endocrinol Metab 85 (2000) 89-94
120. Ibanez L., Potau N., Marcos M.V., et al. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 85 9 (2000) 3251-3255
121. Cusan L., Dupont A., Gomex J., et al. Comparison of flutamide and spironolactone n the treatment of hirsutism: a randomized controlled trial. Fertil Steril 61 (1994) 281-287
122. Tartagni M., Schonauer L.M., De Salvia M.A., et al. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 73 (2000) 718-723
123. Heiner J.S., Greendale G.A., Kawakami A.K., et al. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab 80 (1995) 3412-3418
124. Ettinger B., Selby J., Citron J.T., et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 83 (1994) 693-700
125. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338 13 (1998) 867-872
126. Sattar N., Hopkinson Z.E., and Greer I.A. Insulin-sensitizing agents in polycystic ovary syndrome. Lancet 351 (1998) 305-307
127. Moghetti P., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85 (2000) 139-146
128. Fleming R., Hopkinson Z.E., Wallace A.M., et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo controlled trial. J Clin Endocrinol Metab 87 (2002) 569-574
129. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
130. Diamanti-Kandarakis E., Kouli C., Tsianateli T., et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138 3 (1998) 269-274
131. Morin-Papunen L.C., Koivunen R.M., Roukonen A., et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 691-696
132. Pasquali R., Gambineri A., Biscotti D., et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85 8 (2000) 2767-2774
133. Glueck C.J., Wang P., Fontaine R., et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 29 (2001) 160-169
134. Costello M.F., and Eden J.A. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79 (2003) 1-13
135. Ibanez L., Valls C., Potau N., et al. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 85 (2000) 3526-3530
136. Ibanez L., Valls C., Ferrer A., et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 86 (2001) 3595-3598
137. Bridger T., MacDonald S., Baltzer F., et al. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 160 (2006) 241-246
138. Hoeger K., Davidson K., Kochman L., et al. The impact of metformin, oral contraceptives and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 93 (2008) 4299-4306 [Epub 2008 Aug 26]
139. Stein I.F., and Leventhal M.L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 (1935) 181-191
140. Seow K., Juan C., Hwang J., et al. Laparoscopic surgery in polycystic ovary syndrome: reproductive and metabolic effects. Semin Reprod Med 26 (2008) 101-110
141. Armar N.A., McGarrigle H.H., Honour J., et al. Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril 53 (1990) 45-49